MAPK3 and familial hypercholesterolemia: Similar to our previous study, U0126 alone reduced atherosclerotic lesions, but it had no effect on mouse body weight gain and serum lipid profiles (Figure S1A-D), indicating the anti-atherosclerosis by ERK1/2 inhibitor is un-related to amelioration of hypercholesterolemia.